Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (4614)	11/3/2017 12:39:43 PM
From: richardred	Respond to of 7120

RE-OMI-The market likes today's acquisition news. Corporate News Blog - Owens & Minor to Acquire Halyard’s S&IP Business $OMI To Acquire Halyard’s S&IP Business https://t.co/2XCADnTX38 — CRWE News Wire (@crwenewswire) November 3, 2017

To: richardred who wrote (4614)	11/24/2017 5:54:23 PM
From: richardred	Respond to of 7120

Shanghai Pharmaceuticals to purchase Cardinal Health’s unit Shanghai Pharmaceuticals Holding is acquiring Malaysia-incorporated Cardinal Health L (Cardinal Malaysia) for USD 1,200 billion, subject to further adjustments based on the target’s working capital, existing cash and assumed debt. The buyer has obtained financing from third party financial institutions and is making the purchase via its Shanghai Pharma Century Global arm. Pending approval from China’s Ministry of Commerce, the deal is expected to complete by the end of Cardinal Health’s fiscal year. The target is a holding unit which controls all of the China-based business of Cardinal Health, a New York Stock Exchange-listed pharmaceutical supplier. Billed as a global and integrated healthcare services provider, the Dublin and Ohio-headquartered group operates through five segments: pharmaceutical distribution, medical devices distribution, hospital direct sales, speciality pharmaceuticals and speciality pharmacies and commercial technology. Cardinal Health currently serves almost 11,000 medical institutions and other downstream customers through 30 direct-to-patient pharmacies, 14 direct sales companies and 17 distribution centres in China. It provides drugs, medical devices, surgical supplies, speciality pharmaceuticals, vaccines and diagnostic systems and equipment in major cities ranging from Beijing and Tianjin to Dalian and Wuxi. In all, the business owns a storage area of about 146,000 square metres and 7,000 square metres of cold storage capacity. Cardinal Malaysia posted operating revenue of CNY 25,518 million (USD 3,848 million) and earnings before interest, tax, depreciation and amortisation of CNY 553 million in H1 2017. It also had total and net assets of CNY 12,890 million and CNY 1,909 million, respectively, as of 30th June 2017. The announcement comes as China is planning a reform to tighten oversight of its fragmented healthcare industry, a move that could significantly slow Cardinal Health’s business growth. An unnamed person familiar with the matter previously told Reuters: “The new policy is likely to squeeze margins for most distributors in China. They will be under pressure for future profitability. It does make Cardinal and others worried.” From Shanghai Pharmaceuticals’ perspective, the deal serves to widen its distribution network, particularly in Shanghai, Beijing, Zhejiang, Tianjin and Chongqing, among other locations. Commenting on the transaction, the buyer’s chairman Zhou Jun said: “Amid the national healthcare reform, the acquisition of the Cardinal Health China business will further strengthen our leadership in the distribution and retail pharmacy network, and expedite our transformation to become a modern global healthcare provider.” Last July, Cardinal Health successfully carried out its largest deal on record to buy the medical supplies businesses of Medtronic for USD 6,100 million. In a much smaller transaction early this year, Cardinal Health purchased 6 per cent of Navidea Biopharmaceuticals, an Ohio-based diagnostics and radiopharmaceutical medical products maker, for around USD 7 million. © Zephyr mandaportal.com

To: richardred who wrote (4614)	12/6/2017 8:58:32 PM
From: Glenn Petersen	Respond to of 7120

The acquisition of Aetna by CVS may accelerate Amazon's entry into the prescription drug business. They could easily buy Walgreens, which has a market cap of approximately $70 billion, although that would probably draw antitrust scrutiny from an already nervous Washington D.C. As for the m drug distributors listed in that article I posted, you could probably get better results throwing a dart than trying to predict what Amazon will or will not do.

To: richardred who wrote (4614)	2/21/2018 12:08:04 PM
From: richardred	Respond to of 7120

New small buy today OMI. It's beaten up, but IMO an area for consolidation. This because of new competition by Amazon and other retail pharmacy consolidations in this space. Maybe a good fit for CAH or MCK or Amazon itself ? The company made a recent acquisition for future growth in sales and IMO a way to combat earnings declines. A well covered dividend for the wait for something better to possibly happen . P.S. Amazon has quietly launched an exclusive line of over-the-counter health products cnbc.com